Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a US-based commercial-stage pharmaceutical company, announced on Friday that it has named Zhen Su, MD, MBA as its new director, effective 31 August 2023.

Presently, Dr Su is the chief executive officer and a member of the board of directors at Marengo Therapeutics, Inc. He has served as SVP, global head of Oncology Business Franchise, including US head of the Oncology Business Unit, at Merck KGaA, chief medical officer at EMD Serono and headed leadership functions at Sanofi's Oncology Division and GlaxoSmithKline, faculty of Duke University Medical School and then at the University of Florida, where he was the director of the Cell and Gene Therapy program.

Richard Paulson, MBA, Karyopharm chief executive officer, said, 'Dr Su is a physician scientist and pharmaceutical industry leader who brings tremendous experience guiding products through discovery, clinical development, approval, and global commercialisation. His expertise and counsel will be critical to us as we expand into different patient populations and potential new indications in oncology. We are delighted to welcome him to our team and look forward to the insight he will provide as part of our board of directors.'